Patent EA-004444-B1 (EA)
Title: Genes and proteins and their use
Inventor: HUGHES MARTIN JOHN GLENTON
IPC: A61K48/00
Filed: 1999-12-22
Abstract: 1. A peptide encoded by a gene identified herein as pho 1-13, obtainable from Group B Streptococcus microorganisms, comprising an amino acid sequence SEQ ID NOS. 2, wherein the homologue has at least 60% sequence similarity or a functional fragment thereof for treatment and prophylaxis of conditions associated with bacterial infection caused by said microorganisms. 2. A peptide encoded by a gene identified herein as pho 1-14, obtainable from Group B Streptococcus microorganisms, comprising an amino acid sequence SEQ ID NOS. 4, wherein the homologue has at least 60% sequence similarity or a functional fragment thereof for treatment and prophylaxis of conditions associated with bacterial infection caused by said microorganisms. 3. A peptide encoded by a gene identified herein as pho 1-5, obtainable from Group B Streptococcus microorganisms, comprising an amino acid sequence SEQ ID NOS. 6, wherein the homologue has at least 60% sequence similarity or a functional fragment thereof for treatment and prophylaxis of conditions associated with bacterial infection caused by said microorganisms. 4. A peptide encoded by a gene identified herein as pho 3-3, obtainable from Group B Streptococcus microorganisms, comprising an amino acid sequence SEQ ID NOS. 8, wherein the homologue has at least 60% sequence similarity or a functional fragment thereof for treatment and prophylaxis of conditions associated with bacterial infection caused by said microorganisms. 5. A peptide encoded by a gene identified herein as pho 2-10, obtainable from Group B Streptococcus microorganisms, comprising an amino acid sequence SEQ ID NOS. 2, wherein the homologue has at least 60% sequence similarity or a functional fragm10nt thereof for treatment and prophylaxis of conditions associated with bacterial infection caused by said microorganisms. 6. A peptide encoded by a gene identified herein as pho 2-10, obtainable from Group B Streptococcus microorganisms, comprising an amino acid sequence SEQ ID NOS. 11, wherein the homologue has at least 60% sequence similarity or a functional fragment thereof for treatment and prophylaxis of conditions associated with bacterial infection caused by said microorganisms. 7. A peptide encoded by a gene identified herein as pho 2-15, obtainable from Group B Streptococcus microorganisms, comprising an amino acid sequence SEQ ID NOS. 13, wherein the homologue has at least 60% sequence similarity or a functional fragment thereof for treatment and prophylaxis of conditions associated with bacterial infection caused by said microorganisms. 8. A peptide encoded by a gene identified herein as pho 2-2, obtainable from Group B Streptococcus microorganisms, comprising an amino acid sequence SEQ ID NOS. 15, wherein the homologue has at least 60% sequence similarity or a functional fragment thereof for treatment and prophylaxis of conditions associated with bacterial infection caused by said microorganisms. 9. A peptide encoded by a gene identified herein as pho 3-14, obtainable from Group B Streptococcus microorganisms, comprising an amino acid sequence SEQ ID NOS. 17, wherein the homologue has at least 60% sequence similarity or a functional fragment thereof for treatment and prophylaxis of conditions associated with bacterial infection caused by said microorganisms. 10. A peptide encoded by a gene identified herein as pho 3-17, obtainable from Group B Streptococcus microorganisms, comprising an amino acid sequence SEQ ID NOS. 19, wherein the homologue has at least 60% sequence similarity or a functional fragment thereof for treatment and prophylaxis of conditions associated with bacterial infection caused by said microorganisms. 11. A peptide encoded by a gene identified herein as pho 3-18, obtainable from Group B Streptococcus microorganisms, comprising an amino acid sequence SEQ ID NOS. 21, wherein the homologue has at least 60% sequence similarity or a functional fragment thereof for treatment and prophylaxis of conditions associated with bacterial infection caused by said microorganisms. 12. A peptide encoded by a gene identified herein as pho 3-1, obtainable from Group B Streptococcus microorganisms, comprising an amino acid sequence SEQ ID NOS. 23, wherein the homologue has at least 60% sequence similarity or a functional fragment thereof for treatment and prophylaxis of conditions associated with bacterial infection caused by said microorganisms. 13. A peptide encoded by a gene identified herein as pho 3-21, obtainable from Group B Streptococcus microorganisms, comprising an amino acid sequence SEQ ID NOS. 25, wherein the homologue has at least 60% sequence similarity or a functional fragment thereof for treatment and prophylaxis of conditions associated with bacterial infection caused by said microorganisms. 14. A peptide encoded by a gene identified herein as pho 3-22, obtainable from Group B Streptococcus microorganisms, comprising an amino acid sequence SEQ ID NOS. 27, wherein the homologue has at least 60% sequence similarity or a functional fragment thereof for treatment and prophylaxis of conditions associated with bacterial infection caused by said microorganisms. 15. A peptide encoded by a gene identified herein as pho 3-23, obtainable from Group B Streptococcus microorganisms, comprising an amino acid sequence SEQ ID NOS. 29, wherein the homologue has at least 60% sequence similarity or a functional fragment thereof for treatment and prophylaxis of conditions associated with bacterial infection caused by said microorganisms. 16. A peptide encoded by a gene identified herein as pho 3-24, obtainable from Group B Streptococcus microorganisms, comprising an amino acid sequence SEQ ID NOS. 31, wherein the homologue has at least 60% sequence similarity or a functional fragment thereof for treatment and prophylaxis of conditions associated with bacterial infection caused by said microorganisms. 17. A peptide encoded by a gene identified herein as pho 3-29, obtainable from Group B Streptococcus microorganisms, comprising an amino acid sequence SEQ ID NOS. 33, wherein the homologue has at least 60% sequence similarity or a functional fragment thereof for treatment and prophylaxis of conditions associated with bacterial infection caused by said microorganisms. 18. A peptide encoded by a gene identified herein as pho 3-50, obtainable from Group B Streptococcus microorganisms, comprising an amino acid sequence SEQ ID NOS. 35 wherein the homologue has at least 60% sequence similarity or a functional fragment thereof for treatment and prophylaxis of conditions associated with bacterial infection caused by said microorganisms. 19. A polynucleotide encoding a peptide according to any preceding claim, for therapeutic use. 20. A polynucleotide according to claim 19 including any of the nucleotide sequences identified herein as SEQ ID NOS. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29 or a functional fragment thereof. 21. A vaccine for prophylaxis of conditions associated with bacterial infection caused by Group B Streptococcus comprising a peptide according to any of claims 1 to 18. 22. Use of a peptide according to any of claims 1 to 18 for screening potential antimicrobal drugs. 23. Use of a peptide according to any of claims 1 to 18 for the detection of virulence. 24. Use of a polynucleotide according to any of claims 19 to 20 for screening potential antimicrobal drugs. 25. Use of a polynucleotide according to any of claims 19 to 20 for the detection of virulence. 26. Use of a peptide according to any of claims 19 to 18, for the manufacture of a medicament for use in the treatment or prevention of a condition associated with bacterial infection, wherein the infection is Group B Streptococcus infection. 27. Use of a polynucleotide according to any of claims 19 to 20 for the manufacture of a medicament for use in the treatment or prevention of a condition associated with bacterial infection, wherein the infection is Group B Streptococcus infection. 28. Use according to claim 26 or claim 27, wherein the infection is a focal infection. 29. Use according to claim 26 or claim 27, wherein the infection is a urinary tract infection. 30. An antibody raised against a peptide according to any one of claims 1 to 18.